Short answer
VERACYTE, INC. (VCYT) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $139M (up 21.5% year over year) with net income of $29M.
Q1 2026 key financials · XBRL
- Revenue
- $139M
- +21.5% YoY
- Net income
- $29M
- +307.4% YoY
- Operating margin
- 16.3%
- Gross margin
- 72.7%
- EPS (diluted)
- $0.35
- +288.9% YoY
Source: XBRL data from the VERACYTE, INC. (VCYT) Q1 2026 10-Q on SEC EDGAR. USD.
VERACYTE, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $139.1M, up 21% YoY from $114.5M, driven by testing revenue up 26% to $135.1M
- Gross margin 72.7% vs 69.5% YoY, with net income $28.7M vs $7.0M
- Best segment: testing revenue $135.1M, up $27.8M; worst: biopharmaceutical revenue $0.3M, down 92%
- Total test volume 47,615, up 17%; diagnostic tests 45,248, up 19%, while product tests fell 8%
- Headwinds: payer utilization controls, reimbursement pressure, macroeconomic volatility and international trade policies
Risk Factors
- No risk-factors section provided; material changes from the 10-K cannot be assessed
- Bylaw amendment effective May 1, 2026, adding cure rights for deficiencies in stockholder director-nomination notices
- No officer or director adopted, modified, or terminated a Rule 10b5-1 trading arrangement during the quarter
- No defaults upon senior securities reported for the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other VERACYTE, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.